HK Stock Market Move | FANGZHOU JIANKE (06086) rose by more than 35%, and is expected to achieve a maximum net profit of 10 million yuan in 2025, officially achieving comprehensive profitability.

date
09:41 26/01/2026
avatar
GMT Eight
Ark Pharmabe (06086) rose more than 35%, as of press time, up 35.84% to HK$3.83, with a turnover of HK$134 million.
FANGZHOU JIANKE (06086) rose more than 35%, up 35.84% at the time of publication, reaching HK$3.83, with a transaction volume of HK$134 million. On the news front, on January 25th, FANGZHOU JIANKE issued a positive profit forecast for 2025. The positive profit forecast shows that the company expects to achieve revenue of 3.5-3.55 billion yuan, an increase of about 30% year-on-year; in terms of profit, following the achievement of adjusted profit in 2024, the company is expected to achieve a net profit of 7-10 million yuan in 2025, officially achieving comprehensive profitability. The announcement pointed out that the expected revenue growth is mainly due to the company's model of "close doctor-patient relationships" and the upgrade brought about by AI technology, attracting more doctors and patients to join, thus driving continuous growth in consumer-facing business. The turnaround from a loss to a profit is mainly due to revenue growth, as well as a decrease in trading based on equity settlement, pushing the company to achieve a qualitative change from loss to profit.